Search

Your search keyword '"Ruxrungtham,, Kiat"' showing total 1,177 results
Start Over Author "Ruxrungtham,, Kiat"
1,177 results on '"Ruxrungtham,, Kiat"'

1. Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study

Author

Puthanakit, Thanyawee, Prompetchara, Eakachai, Gatechompol, Sivaporn, Ketloy, Chutitorn, Thitithanyanont, Arunee, Jongkaewwattana, Anan, Buranapraditkun, Supranee, Ubolyam, Sasiwimol, Kerr, Stephen J., Sophonphan, Jiratchaya, Apornpong, Tanakorn, Kittanamongkolchai, Wonngarm, Siwamogsatham, Sarawut, Sriplienchan, Somchai, Patarakul, Kanitha, Theerawit, Tuangtip, Promsena, Pathariya, Nantanee, Rapisa, Manomaisantiphap, Siwaporn, Chokyakorn, Sarun, Hong, Lina, Samija, Mijo, Montefiori, David C., Gao, Hongmei, Eaton, Amanda, Wijagkanalan, Wassana, Alameh, Mohamad-Gabriel, Weissman, Drew, and Ruxrungtham, Kiat

Published
2024
Full Text
View/download PDF

2. Recommendations on data sharing in HIV drug resistance research

Author

Inzaule, Seth C, Siedner, Mark J, Little, Susan J, Avila-Rios, Santiago, Ayitewala, Alisen, Bosch, Ronald J, Calvez, Vincent, Ceccherini-Silberstein, Francesca, Charpentier, Charlotte, Descamps, Diane, Eshleman, Susan H, Fokam, Joseph, Frenkel, Lisa M, Gupta, Ravindra K, Ioannidis, John PA, Kaleebu, Pontiano, Kantor, Rami, Kassaye, Seble G, Pond, Sergei L Kosakovsky, Kouamou, Vinie, Kouyos, Roger D, Kuritzkes, Daniel R, Lessells, Richard, Marcelin, Anne-Genevieve, Mbuagbaw, Lawrence, Minalga, Brian, Ndembi, Nicaise, Neher, Richard A, Paredes, Roger, Pillay, Deenan, Raizes, Elliot G, Rhee, Soo-Yon, Richman, Douglas D, Ruxrungtham, Kiat, Sabeti, Pardis C, Schapiro, Jonathan M, Sirivichayakul, Sunee, Steegen, Kim, Sugiura, Wataru, van Zyl, Gert U, Vandamme, Anne-Mieke, Wensing, Annemarie MJ, Wertheim, Joel O, Gunthard, Huldrych F, Jordan, Michael R, and Shafer, Robert W

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Antimicrobial Resistance, Sexually Transmitted Infections, Infectious Diseases, HIV/AIDS, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Humans, HIV Infections, Phylogeny, HIV-1, Drug Resistance, Viral, Anti-Retroviral Agents, Mutation, Anti-HIV Agents, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

• Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that may be less effective, less well-tolerated, and more expensive than those used in first-line regimens.  • HIV drug resistance studies are designed to determine which HIV mutations are selected by antiretroviral drugs and, in turn, how these mutations affect antiretroviral drug susceptibility and response to future antiretroviral treatment regimens.  • Such studies collectively form a vital knowledge base essential for monitoring global HIV drug resistance trends, interpreting HIV genotypic tests, and updating HIV treatment guidelines.  • Although HIV drug resistance data are collected in many studies, such data are often not publicly shared, prompting the need to recommend best practices to encourage and standardize HIV drug resistance data sharing.  • In contrast to other viruses, sharing HIV sequences from phylogenetic studies of transmission dynamics requires additional precautions as HIV transmission is criminalized in many countries and regions.  • Our recommendations are designed to ensure that the data that contribute to HIV drug resistance knowledge will be available without undue hardship to those publishing HIV drug resistance studies and without risk to people living with HIV.

Published
2023

3. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

Author

Douglas, Pamela S, Umbleja, Triin, Bloomfield, Gerald S, Fichtenbaum, Carl J, Zanni, Markella V, Overton, Edgar T, Fitch, Kathleen V, Kileel, Emma M, Aberg, Judith A, Currier, Judith, Sponseller, Craig A, Melbourne, Kathleen, Avihingsanon, Anchalee, Bustorff, Flavio, Estrada, Vicente, Ruxrungtham, Kiat, Saumoy, Maria, Navar, Ann Marie, Hoffmann, Udo, Ribaudo, Heather J, and Grinspoon, Steven

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Sexually Transmitted Infections, Nutrition, Clinical Research, Clinical Trials and Supportive Activities, HIV/AIDS, Minority Health, Infectious Diseases, Prevention, Physical Activity, Good Health and Well Being, Blood Glucose, Body Mass Index, Cardiovascular Diseases, Female, HIV, HIV Infections, Heart Disease Risk Factors, Humans, Male, Risk Factors, atherosclerotic cardiovascular disease, cardiac prevention, cardiovascular health, cardiovascular risk, lifestyle modifications, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundIn addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH).MethodsAmong participants in the global REPRIEVE randomized trial, we characterized demographics and HIV characteristics relative to ACC/AHA pooled cohort equations (PCE) for atherosclerotic CV disease predicted risk and CV health evaluated by Life's Simple 7 (LS7; includes smoking, diet, physical activity, body mass index, blood pressure, total cholesterol, and glucose).ResultsAmong 7382 REPRIEVE participants (31% women, 45% Black), the median PCE risk score was 4.5% (lower and upper quartiles Q1, Q3: 2.2, 7.2); 29% had a PCE score

Published
2021

4. Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice

Author

Prompetchara, Eakachai, Ketloy, Chutitorn, Alameh, Mohamad-Gabriel, Tharakhet, Kittipan, Kaewpang, Papatsara, Yostrerat, Nongnaphat, Pitakpolrat, Patrawadee, Buranapraditkun, Supranee, Manopwisedjaroen, Suwimon, Thitithanyanont, Arunee, Jongkaewwattana, Anan, Hunsawong, Taweewan, Im-Erbsin, Rawiwan, Reed, Matthew, Wijagkanalan, Wassana, Patarakul, Kanitha, Techawiwattanaboon, Teerasit, Palaga, Tanapat, Lam, Kieu, Heyes, James, Weissman, Drew, and Ruxrungtham, Kiat

Published
2023
Full Text
View/download PDF

7. Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial

Author

Gatechompol, Sivaporn, Kittanamongkolchai, Wonngarm, Ketloy, Chutitorn, Prompetchara, Eakchai, Thitithanyanont, Arunee, Jongkaewwattana, Anan, Buranapraditkun, Supranee, Alameh, Mohamad-Gabriel, Ubolyam, Sasiwimol, Sophonphan, Jiratchaya, Apornpong, Tanakorn, Kerr, Stephen, Kamarulzaman, Adeeba, Siwamogsatham, Sarawut, Kroon, Eugène, Puthanakit, Thanyawee, Patarakul, Kanitha, Palaga, Tanapat, Wijagkanalan, Wassana, Carpenter, Alexis, Hong, Lina, Weissman, Drew, and Ruxrungtham, Kiat

Published
2022
Full Text
View/download PDF

8. Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

Author

Teeratakulpisarn, Nipat, Pattanachaiwit, Supanit, Sriplienchan, Somchai, Tantivitayakul, Ponpen, Kanaprach, Ratchapong, Ruxrungtham, Kiat, Dumrongpisutikul, Netsiri, Rojnuckarin, Ponlapat, Chottanapund, Suthat, Poltavee, Kultida, Luekasemsuk, Tassanee, Savadsuk, Hathairat, Puttamsawin, Suwanna, Benjapornpong, Khunthalee, Ratnaratorn, Nisakorn, Tangnaree, Kamonkan, Munkong, Chutharat, Thaimanee, Rommanus, Eamyoung, Patcharin, Ubolyam, Sasiwimol, Lerdlum, Sukalya, Manasnayakorn, Sopark, Rerknimitr, Rugsun, Sirivichayakul, Sunee, Wattanaboonyongcharoen, Phandee, Cowden, Jessica, Schuetz, Alexandra, Akapirat, Siriwat, Churikanont, Nampueng, Getchalarat, Saowanit, Hsu, Denise, Turk, Ellen, Butterworth, Oratai, Milazzo, Mark, Eller, Leigh Anne, Ake, Julie, Spudich, Serena, Fox, CAPT Lawrence, Ratto-Kim, Silvia, DeGruttola, Victor, Chinvarun, Yotin, Sithinamsuwan, Pasiri, Fletcher, James, Shiramizu, Bruce, Takata, Hiroshi, Kakazu, Juyeon C., Mitchell, Julie L., Kroon, Eugene, Colby, Donn J., Sacdalan, Carlo, Bai, Hongjun, Ehrenberg, Philip K., Geretz, Aviva, Buranapraditkun, Supranee, Pinyakorn, Suteeraporn, Intasan, Jintana, Tipsuk, Somporn, Suttichom, Duanghathai, Prueksakaew, Peeriya, Chalermchai, Thep, Chomchey, Nitiya, Phanuphak, Nittaya, de Souza, Mark, Michael, Nelson L., Robb, Merlin L., Haddad, Elias K., Crowell, Trevor A, Vasan, Sandhya, Valcour, Victor G., Douek, Daniel C., Thomas, Rasmi, Rolland, Morgane, Chomont, Nicolas, Ananworanich, Jintanat, and Trautmann, Lydie

Published
2022
Full Text
View/download PDF

9. Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy

Author

Suwanpimolku, Gompol, Gatechompol, Sivaporn, Kawkitinarong, Kamon, Ueaphongsukkit, Thornthun, Sophonphan, Jiratchaya, Siriyakorn, Nirada, Jirajariyavej, Supunnee, Khusuwan, Suwimon, Panarat, Palakorn, Wannalerdsakun, Surat, Saetiew, Natcha, Chayangsu, Sunee, Wiwatrojanagul, Sirichai, Noopetch, Preudtipong, Danpornprasert, Praniti, Mekviwattanawong, Sripetcharat, Fujitnirun, Chris, Lertpiriyasuwat, Cheewanan, Han, Win Min, Kerr, Stephen J., Ruxrungtham, Kiat, and Avihingsanon, Anchalee

Subjects
Statistics, Care and treatment, Risk factors, HIV patients -- Statistics -- Care and treatment, Highly active antiretroviral therapy -- Statistics, Tuberculosis -- Statistics -- Risk factors
Abstract

1 | INTRODUCTION Despite the availability of effective antiretroviral therapy (ART), tuberculosis (TB) remains the leading cause of morbidity and mortality among people living with human immunodeficiency virus (PLWH). The [...], Introduction: Among high tuberculosis (TB) and HIV burden countries in Asia, tuberculosis preventive therapy (TPT) in people living with HIV (PLWH) has been underutilized despite its proven benefits independent of antiretroviral therapy (ART). Therefore, we determined the incidence of active TB and mortality among 9179 adult PLWH who attended and received ART from 15 tertiary care hospitals across Thailand. Methods: A retrospective study was conducted in 2018 using follow-up data from 1999 to 2018. The primary endpoint was incident TB disease after ART initiation. Factors associated with TB incidence were analysed using competing risk regression. The Kaplan-Meier method was used to estimate mortality after ART initiation. Results: During a median of 5.1 years of ART (IQR 2.2-9.5 years), 442 (4.8%) PLWH developed TB (TB/HIV), giving an over-all incidence of 750 (95% CI 683-823) per 100,000 persons-year of follow up (PYFU). In multivariate analysis, lower CD4 at ART initiation ([less than or equal to]100 cells/[mm.sup.3], adjusted sub-distribution hazard ratio [aSHR]: 2.08, 95% CI, 1.47-2.92; 101-200 cells/[mm.sup.3], aSHR: 2.21, 95% CI, 1.54-3.16; 201-350 cells/[mm.sup.3], aSHR: 1.59, 95% CI, 1.11-2.28 vs. >350 cells/[mm.sup.3]), male sex (aSHR: 1.40, 95% CI, 1.11-1.78), lower body weight ( Conclusions: In this high TB burden country, TB incidence was remarkably high during the first few years after ART initiation and thereafter decreased significantly. Rapid ART initiation and appropriate TPT can be potential key interventions to tackle the TB epidemic and reduce mortality among PLWH in TB/HIV high burden settings. Keywords: antiretroviral therapy; Asia; HIV; incident tuberculosis; latent TB infection; Thailand

Published
2022
Full Text
View/download PDF

12. A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study.

Author

Suratannon, Narissara, Limsuwan, Ticha, Tantilipikorn, Pongsakorn, Chatchatee, Pantipa, Saengapaswiriya, Atik, Boonpiyathad, Tadech, Thongngarm, Torpong, Roongpuvapaht, Boonsam, Hiroshi Chantaphakul, Kulalert, Prapasri, Thanaviratananich, Sanguansak, Sangsupawanich, Pasuree, Fooanant, Supranee, Manuyakorn, Wiparat, Chusakul, Supinda, Piboonpochanun, Orathai, Apornpong, Tanakorn, Jongkonnee Wongpiyabovorn, and Ruxrungtham, Kiat

Published
2024
Full Text
View/download PDF

15. Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study

Author

Folschweiller, Nicolas, Teixeira, Julio, Joshi, Smita, Goldani, Luciano Z, Supparatpinyo, Khuanchai, Basu, Partha, Chotpitayasunondh, Tawee, Chetchotisakd, Ploenchan, Ruxrungtham, Kiat, Roteli-Martins, Cecilia, Grinsztejn, Beatriz, Quintana, Silvana Maria, Kumarasamy, Nagalingeswaran, Poongulali, Selvamuthu, Kulkarni, Vinay, Lin, Lan, Datta, Sanjoy K, Descamps, Dominique, Dodet, Monique, Dubin, Gary, Friel, Damien, Hezareh, Marjan, Karkada, Naveen, Meric Camilleri, Dorothee, Poncelet, Sylviane, Salaun, Bruno, Tavares-da-Silva, Fernanda, Thomas-Jooris, Florence, and Struyf, Frank

Published
2020
Full Text
View/download PDF

18. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

Author

Davey, Richard T, Fernández-Cruz, Eduardo, Markowitz, Norman, Pett, Sarah, Babiker, Abdel G, Wentworth, Deborah, Khurana, Surender, Engen, Nicole, Gordin, Fred, Jain, Mamta K, Kan, Virginia, Polizzotto, Mark N, Riska, Paul, Ruxrungtham, Kiat, Temesgen, Zelalem, Lundgren, Jens, Beigel, John H, Lane, H Clifford, Neaton, James D, Butts, Jessica, Denning, Eileen, DuChene, Alain, Krum, Eric, Harrison, Merrie, Meger, Sue, Peterson, Ross, Quan, Kien, Shaughnessy, Megan, Thompson, Greg, Vock, David, Metcalf, Julia, Dewar, Robin, Rehman, Tauseef, Natarajan, Ven, McConnell, Rose, Flowers, Emily, Smith, Kenny, Hoover, Marie, Coyle, Elizabeth M, Munroe, David, Aagaard, Bitten, Pearson, Mary, Cursley, Adam, Webb, Helen, Hudson, Fleur, Russell, Charlotte, Sy, Aminata, Purvis, Cara, Jackson, Brooke, Collaco-Moraes, Yolanda, Carey, Dianne, Robson, Rosemary, Sánchez, Adriana, Finley, Elizabeth, Conwell, Donna, Losso, Marcelo H, Gambardella, Luciana, Abela, Cecilia, Lopez, Paco, Alonso, Helena, Touloumi, Giota, Gioukari, Vicky, Anagnostou, Olga, Avihingsanon, Anchalee, Pussadee, Kanitta, Ubolyam, Sasiwimol, Omotosho, Bola, Solórzano, Clemencia, Petersen, Tianna, Vysyaraju, Kranthi, Rizza, Stacey A, Whitaker, Jennifer A, Nahra, Raquel, Baxter, John, Coburn, Patricia, Gardner, Edward M, Scott, James A, Faber, Leslie, Pastor, Erica, Makohon, Linda, MacArthur, Rodger A, Hillman, L Monique, Farrough, Marti J, Polenakovik, Hari M, Clark, Linda A, Colon, Roberto J, Kunisaki, Ken M, DeConcini, Miranda, Johnson, Susan A, Wolfe, Cameron R, Mkumba, Laura, Carbonneau, June Y, Morris, Alison, Fitzpatrick, Meghan E, Kessinger, Cathy J, Salata, Robert A, Arters, Karen A, Tasi, Catherine M, Panos, Ralph J, Lach, Laura A, Glesby, Marshall J, Ham, Kirsis A, Hughes, Valery G, Schooley, Robert T, Crouch, Daniel, Muttera, Leticia, Novak, Richard M, Bleasdale, Susan C, Zuckerman, Ariel E, Manosuthi, Weerawat, Thaonyen, Supeda, Chiewcharn, Thaniya, Suwanpimolkul, Gompol, Gatechumpol, Sivaporn, Bunpasang, Sirikunya, Angus, Brian J, Anderson, Monique, Morgan, Marcus, Minton, Jane, Gkamaletsou, Maria N, Hambleton, Joe, Price, David A, Llewelyn, Martin J, Sweetman, Jonathan, Carbone, Javier, Arribas, Jose R, Montejano, Rocio, Lobo Beristain, Jose L, Martinez, Iñaki Z, Barberan, Jose, Hernandez, Paola, Dwyer, Dominic E, Kok, Jen, Borges, Alvaro, Brandt, Christian T, Knudsen, Lene S, Sypsas, Nikolaos, Constantinou, Costas, Markogiannakis, Antonios, Zakynthinos, Spyros, Katsaounou, Paraskevi, Kalomenidis, Ioannis, Mykietiuk, Analia, Alzogaray, Maria F, Obed, Mora, Macias, Laura M, Ebensrtejin, Juan, Burgoa, Patricia, Nannini, Esteban, Lahitte, Matias, Perez-Patrigeon, Santiago, Martínez-Orozco, José Arturo, Ramírez-Hinojosa, Juan Pablo, and Davey, Richard T, Jr

Published
2019
Full Text
View/download PDF

26. Cognitive Function and Neurodevelopmental Outcomes in HIV-infected Children Older Than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy

Author

Puthanakit, Thanyawee, Ananworanich, Jintanat, Vonthanak, Saphonn, Kosalaraksa, Hansudewechakul, Rawiwan, van der Lugt, Jasper, Kerr, Stephen J, Kanjanavanit, Suparat, Ngampiyaskul, Chaiwat, Wongsawat, Jurai, Luesomboon, Wicharn, Vibol, Ung, Pruksakaew, Kanchana, Suwarnlerk, Tulathip, Apornpong, Tanakorn, Ratanadilok, Kattiya, Paul, Robert, Mofenson, Lynne M, Fox, Lawrence, Valcour, Victor, Brouwers, Pim, and Ruxrungtham, Kiat

Subjects
Prevention, Pediatric, Mental Health, Neurosciences, HIV/AIDS, Clinical Trials and Supportive Activities, Behavioral and Social Science, Infectious Diseases, Clinical Research, Good Health and Well Being, Anti-HIV Agents, Cambodia, Child, Child, Preschool, Cognitive Dysfunction, Cohort Studies, Drug Administration Schedule, Female, HIV Infections, Humans, Infant, Intelligence Tests, Male, Thailand, Treatment Outcome, HIV, children, antiretroviral therapy, neurodevelopment, resource-limited settings, PREDICT Study Group, Paediatrics and Reproductive Medicine, Public Health and Health Services, Pediatrics
Abstract

BackgroundWe previously reported similar AIDS-free survival at 3 years in children who were >1 year old initiating antiretroviral therapy (ART) and randomized to early versus deferred ART in the Pediatric Randomized to Early versus Deferred Initiation in Cambodia and Thailand (PREDICT) study. We now report neurodevelopmental outcomes.MethodsTwo hundred eighty-four HIV-infected Thai and Cambodian children aged 1-12 years with CD4 counts between 15% and 24% and no AIDS-defining illness were randomized to initiate ART at enrollment ("early," n = 139) or when CD4 count became

Published
2013

27. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy

Author

Bunupuradah, Torsak, Chetchotisakd, Ploenchan, Jirajariyavej, Supunnee, Valcour, Victor, Bowonwattanuwong, Chureeratana, Munsakul, Warangkana, Klinbuayaem, Virat, Prasithsirikul, Wisit, Sophonphan, Jiratchaya, Mahanontharit, Apicha, Hirschel, Bernard, Bhakeecheep, Sorakij, Ruxrungtham, Kiat, Ananworanich, Jintanat, and On behalf of the HIV STAR Study Group

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Mental Health, Clinical Research, HIV/AIDS, Depression, Brain Disorders, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adenine, Adult, CD4 Lymphocyte Count, Cognition Disorders, Female, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Lamivudine, Lopinavir, Male, Organophosphonates, RNA, Viral, Reverse Transcriptase Inhibitors, Ritonavir, Tenofovir, Viral Load, Lopinavir/ritonavir monotherapy, Neurocognitive impairment, Central nervous system penetration effectiveness score, HIV STAR Study Group, Medical Microbiology, Neurosciences, Virology, Clinical sciences, Medical microbiology
Abstract

We compared rates of neurocognitive impairment (NCI) among 93 Thai adults failing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination antiretroviral therapy (cART) before and after switching to lopinavir/ritonavir monotherapy (mLPV/r) vs. tenofovir/lamivudine/LPV/r (TDF/3TC/LPV/r). Participants completed the Color Trails 1 and 2, Digit Symbol, and Grooved Pegboard at weeks 0, 24, and 48. We calculated z-scores using normative data from 451 healthy HIV-negative Thais. We defined NCI as performance of

Published
2012

28. Incident Liver Cirrhosis, Associated Factors, and Cardiovascular Disease Risks Among People Living With HIV: A Longitudinal Study

Author

Han, Win Min, Ueaphongsukkit, Thornthun, Chattranukulchai, Pairoj, Siwamogsatham, Sarawut, Chaiteerakij, Roongruedee, Sophonphan, Jiratchaya, Gatechompol, Sivaporn, Ubolyam, Sasiwimol, Phonphithak, Supalak, Ruxrungtham, Kiat, Tangkijvanich, Pisit, Avihingsanon, Yingyos, Kerr, Stephen J., and Avihingsanon, Anchalee

Published
2021
Full Text
View/download PDF

30. Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques

Author

Keelapang, Poonsook, primary, Ketloy, Chutitorn, additional, Puttikhunt, Chunya, additional, Sriburi, Rungtawan, additional, Prompetchara, Eakachai, additional, Sae-Lim, Malinee, additional, Siridechadilok, Bunpote, additional, Duangchinda, Thaneeya, additional, Noisakran, Sansanee, additional, Charoensri, Nicha, additional, Suriyaphol, Prapat, additional, Suparattanagool, Piyanan, additional, Utaipat, Utaiwan, additional, Masrinoul, Promsin, additional, Avirutnan, Panisadee, additional, Mongkolsapaya, Juthathip, additional, Screaton, Gavin, additional, Auewarakul, Prasert, additional, Malaivijitnond, Suchinda, additional, Yoksan, Sutee, additional, Malasit, Prida, additional, Ruxrungtham, Kiat, additional, Pulmanausahakul, Rojjanaporn, additional, and Sittisombut, Nopporn, additional

Published
2023
Full Text
View/download PDF

32. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

Author

Cahn, Pedro Enrique, Cassetti, Lidia Isabel, Porteiro Barreira, Norma, Angel, Jonathan Benjamin, de Pokomandy, Alexandra, Harris, Marianne, Rachlis, Anita R., Walmsley, Sharon L., Allavena, Clotilde, Bouchaud, Oliver, Gatey, Caroline, Rami, Agathe, Casari, Salvatore, Di Perri, Giovanni, Lazzarin, Adriano, Maggiolo, Franco, Penco, Giovanni, Quirino, Tiziana, Rizzardini, Giuliano, Andrade-Villanueva, Jaime-Federico, Sierra-Madero, Juan G., Branco, Teresa, Serrao, Rosario, Teofilo, Eugenio JR., Melendez-Rivera, Ivan, Santiago, Lizette, Zorrilla, Carmen D., Belonosova, Elena, Chernova, Oksana E., Pokrovsky, Vadim, Rakhmanova, Aza Gasanovna, Tsybakova, Olga, Voronin, Eugene, Orrell, Catherine, Vally, Tasneem, Farisani, Livhuwani ML., Sebopa, Boitumelo Lucrecia, Barros, Carlos Aguado, Cano Sánchez, Alfredo, Castaño, Manuel, Falcó Ferrer, Vicens, González García, Juan J., Hernandez-Quero, Jose, Negredo Puigmal, Eugenia, Pérez Elías, María Jesús, Podzamczer Palter, Daniel, Portilla, Joaquin Sogorb, Viciana Fernández, Pompeyo, Manosuthi, Weerawat, Ruxrungtham, Kiat, Dockrell, David H., Hay, Phillip E., Johnson, Margaret A., Mackie, Nicola E., Orkin, Chloe M., Taylor, Steve, Bhatti, Laveeza, Brar, Indira, Brennan, Robert Owen, Cade, Jerry L., Casanas, Beata, Casey, Kathleen, Cunningham, Douglas, DeJesus, Edwin, Dietz, Craig, Dretler, Robin Henry, Eron, Joseph J., Jr., Felizarta, Franco Antoni B., Fife, Kenneth H., Hagins, Debbie P., Hoffman-Terry, Margaret, Jain, Mamta, Johnson, Marc Alexander, Kinder, Clifford A., Kumar, Princy N., Lewis, Stanley T., Jr., McDonald, Cheryl Kay, Meza, Armando D., Mounzer, Karam C., Newman, Cheryl L., Osiyemi, Olayemi O., Poblete, Ronald, Presti, Rachel M., Ramgopal, Moti, Rosenstock, Joel, Samuel, Rafik, Sandkovsky, Uriel Sebastian, Shon, Alyssa So Young, Skiest, Daniel J., Sloan, Louis M., Small, Catherine B., Tebas, Pablo, Van Dam, Cornelius N., Hagins, Debbie P, Porteiro, Norma, Walmsley, Sharon, Falcó, Vicenç, Man, Choy Y, Aylott, Alicia, Buchanan, Ann M, Wynne, Brian, Vavro, Cindy, Aboud, Michael, and Smith, Kimberly Y

Published
2017
Full Text
View/download PDF

33. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

Author

Winnie, Michael, Dinh, Dinh V, Seethala, Raghu, Garcia, Hiram, Pouzar, Joe, Seep, Michael, Riffer, Ernie, Bart, Belinda, Dar, Sadia, Hoppers, Melanie, Panuto, John, Rowe, Heather, Slandzicki, Alex, Wolfe, Cameron, Desantis, Donna, Baynton, Barr, Beasley, Richard L, Markowitz, Norman, Stearns, Zebediah A, Cho, Josalyn, Goisse, Marcy, Wolf, Thomas A, Kay, Jennifer, Dharan, Nila, Fitzgibbons, William, Woodruff, Mark, Bell, Todd, Lenzmeier, Thomas, Schooley, Robert, Elie, Marie-Carmelle, Winokur, Patricia, Finberg, Robert, Hurt, Christopher, Tebas, Pablo, Sattler, Fred R, Ampajwala, Madhavi, Batts, Donald, Bloch, Mark, Moore, Richard, Dwyer, Dominic, Romo-Garcia, Javier, Patrigeon, Santiago Perez, Zulueta, Ana Patricia Rodríguez, Manosuthi, Weerawat, Chetchotisakd, Ploenchan, Ruxrungtham, Kiat, Avihingsanon, Anchalee, Suwanpimolkul, Gompol, Ratanasuwan, Winai, Lupo, Sergio, Trape, Liliana, Losso, Marcelo H, Macias, Laura M, Lopardo, Gustavo, Barcelona, Laura, Mykietuk, Analia, Alzogaray, Maria F, Beigel, John H, Bao, Yajing, Beeler, Joy, Dar, Sadia M, Perez-Patrigeon, Santiago, McClure, Natalie, Bozzolo, Dawn R, Myers, Christopher, Holley, H Preston, Jr, Hoopes, Justin, Lane, H Clifford, Hughes, Michael D, and Davey, Richard T

Published
2017
Full Text
View/download PDF

42. Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody

Author

Keelapang, Poonsook, primary, Kraivong, Romchat, additional, Pulmanausahakul, Rojjanaporn, additional, Sriburi, Rungtawan, additional, Prompetchara, Eakachai, additional, Kaewmaneephong, Jutamart, additional, Charoensri, Nicha, additional, Pakchotanon, Pattarakul, additional, Duangchinda, Thaneeya, additional, Suparattanagool, Piyanan, additional, Luangaram, Prasit, additional, Masrinoul, Promsin, additional, Mongkolsapaya, Juthathip, additional, Screaton, Gavin, additional, Ruxrungtham, Kiat, additional, Auewarakul, Prasert, additional, Yoksan, Sutee, additional, Malasit, Prida, additional, Puttikhunt, Chunya, additional, Ketloy, Chutitorn, additional, and Sittisombut, Nopporn, additional

Published
2023
Full Text
View/download PDF

44. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial

Author

Bunupuradah, Torsak, Kiertiburanakul, Sasisopin, Avihingsanon, Anchalee, Chetchotisakd, Ploenchan, Techapornroong, Malee, Leerattanapetch, Niramon, Kantipong, Pacharee, Bowonwatanuwong, Chureeratana, Banchongkit, Sukit, Klinbuayaem, Virat, Mekviwattanawong, Sripetcharat, Nimitvilai, Sireethorn, Jirajariyavej, Supunnee, Prasithsirikul, Wisit, Munsakul, Warangkana, Bhakeecheep, Sorakij, Chaivooth, Suchada, Phanuphak, Praphan, Cooper, David A, Apornpong, Tanakorn, Kerr, Stephen J, Emery, Sean, and Ruxrungtham, Kiat

Published
2016
Full Text
View/download PDF

45. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Author

Gregson, John, Tang, Michele, Ndembi, Nicaise, Hamers, Raph L, Rhee, Soo-Yon, Marconi, Vincent C, Diero, Lameck, Brooks, Katherine A, Theys, Kristof, Rinke de Wit, Tobias, Arruda, Monica, Garcia, Frederico, Monge, Susana, Günthard, Huldrych F, Hoffmann, Christopher J, Kanki, Phyllis J, Kumarasamy, Nagalingeshwaran, Kerschberger, Bernard, Mor, Orna, Charpentier, Charlotte, Todesco, Eva, Rokx, Casper, Gras, Luuk, Helvas, Elias K, Sunpath, Henry, Di Carlo, Domenico, Antinori, Antonio, Andreoni, Massimo, Latini, Alessandra, Mussini, Cristina, Aghokeng, Avelin, Sonnerborg, Anders, Neogi, Ujjwal, Fessel, William J, Agolory, Simon, Yang, Chunfu, Blanco, Jose L, Juma, James M, Smit, Erasmus, Schmidt, Daniel, Watera, Christine, Asio, Juliet, Kurungi, Wilford, Tostevin, Anna, El-Hay, Tal, Clumeck, Nathan, Goedhals, Dominique, Van Vuuren, Cloete, Bester, Philip A, Sabin, Caroline, Mukui, Irene, Santoro, MARIA M, Perno, Carlo F, Hunt, Gillian, Morris, Lynn, Camacho, Ricardo, De Oliveira, Tulio, Pillay, Deenan, Schulter, Eugene, Murakami-Ogasawara, Akio, Reyes-Terán, Gustavo, Romero, Karla, Avila-Rios, Santiago, Sirivichayakul, Sunee, Ruxrungtham, Kiat, Mekprasan, Suwanna, Dunn, David, Kaleebu, Pontiano, Raizes, Elliot, Kantor, Rami, Shafer, Robert W, and Gupta, Ravindra K

Published
2016
Full Text
View/download PDF

46. Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study

Author

Maraviroc Switch (MARCH) Study Group, Pett, Sarah Lilian, Amin, Janaki, Horban, Andrejz, Andrade-Villanueva, Jaime, Losso, Marcelo, Porteiro, Norma, Madero, Juan Sierra, Belloso, Waldo, Tu, Elise, Silk, David, Kelleher, Anthony, Harrigan, Richard, Clark, Andrew, Sugiura, Wataru, Wolff, Marcelo, Gill, John, Gatell, Jose, Fisher, Martin, Clarke, Amanda, Ruxrungtham, Kiat, Prazuck, Thierry, Kaiser, Rolf, Wolley, Ian, Arnaiz, Juan Alberto, Cooper, David, Rockstroh, Jürgen K., Mallon, Patrick, and Emery, Sean

Published
2016

50. Recommendations on data sharing in HIV drug resistance research.

Author

Avila-Rios, Santiago, Avila-Rios, Santiago, Ayitewala, Alisen, Bosch, Ronald, Calvez, Vincent, Ceccherini-Silberstein, Francesca, Charpentier, Charlotte, Descamps, Diane, Eshleman, Susan, Fokam, Joseph, Frenkel, Lisa, Gupta, Ravindra, Ioannidis, John, Kaleebu, Pontiano, Kantor, Rami, Kassaye, Seble, Kosakovsky Pond, Sergei, Kouamou, Vinie, Kouyos, Roger, Kuritzkes, Daniel, Lessells, Richard, Marcelin, Anne-Genevieve, Mbuagbaw, Lawrence, Inzaule, Seth, Siedner, Mark, Minalga, Brian, Ndembi, Nicaise, Neher, Richard, Paredes, Roger, Pillay, Deenan, Raizes, Elliot, Rhee, Soo-Yon, Ruxrungtham, Kiat, Sabeti, Pardis, Schapiro, Jonathan, Sirivichayakul, Sunee, Steegen, Kim, Sugiura, Wataru, van Zyl, Gert, Vandamme, Anne-Mieke, Wensing, Annemarie, Wertheim, Joel, Gunthard, Huldrych, Jordan, Michael, Shafer, Robert, Little, Susan, Richman, Douglas, Avila-Rios, Santiago, Avila-Rios, Santiago, Ayitewala, Alisen, Bosch, Ronald, Calvez, Vincent, Ceccherini-Silberstein, Francesca, Charpentier, Charlotte, Descamps, Diane, Eshleman, Susan, Fokam, Joseph, Frenkel, Lisa, Gupta, Ravindra, Ioannidis, John, Kaleebu, Pontiano, Kantor, Rami, Kassaye, Seble, Kosakovsky Pond, Sergei, Kouamou, Vinie, Kouyos, Roger, Kuritzkes, Daniel, Lessells, Richard, Marcelin, Anne-Genevieve, Mbuagbaw, Lawrence, Inzaule, Seth, Siedner, Mark, Minalga, Brian, Ndembi, Nicaise, Neher, Richard, Paredes, Roger, Pillay, Deenan, Raizes, Elliot, Rhee, Soo-Yon, Ruxrungtham, Kiat, Sabeti, Pardis, Schapiro, Jonathan, Sirivichayakul, Sunee, Steegen, Kim, Sugiura, Wataru, van Zyl, Gert, Vandamme, Anne-Mieke, Wensing, Annemarie, Wertheim, Joel, Gunthard, Huldrych, Jordan, Michael, Shafer, Robert, Little, Susan, and Richman, Douglas

Abstract

• Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that may be less effective, less well-tolerated, and more expensive than those used in first-line regimens. • HIV drug resistance studies are designed to determine which HIV mutations are selected by antiretroviral drugs and, in turn, how these mutations affect antiretroviral drug susceptibility and response to future antiretroviral treatment regimens. • Such studies collectively form a vital knowledge base essential for monitoring global HIV drug resistance trends, interpreting HIV genotypic tests, and updating HIV treatment guidelines. • Although HIV drug resistance data are collected in many studies, such data are often not publicly shared, prompting the need to recommend best practices to encourage and standardize HIV drug resistance data sharing. • In contrast to other viruses, sharing HIV sequences from phylogenetic studies of transmission dynamics requires additional precautions as HIV transmission is criminalized in many countries and regions. • Our recommendations are designed to ensure that the data that contribute to HIV drug resistance knowledge will be available without undue hardship to those publishing HIV drug resistance studies and without risk to people living with HIV.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results